Marché des médicaments pour les troubles de stockage lysosomal - Rapport d'analyse de la taille, de la part et des tendances du marché mondial - Aperçu de l'industrie et prévisions jusqu'en 2032

Global Lysosomal Storage Disorder Drugs Market

Taille du marché en milliards USD

TCAC : 9.40 %

USD 10.76 Billion USD 21.93 Billion 2024 2032

Période de prévision	2025 –2032
Taille du marché (année de référence)	USD 10.76 Billion
Taille du marché (année de prévision)	USD 21.93 Billion
TCAC	9.40 %
Principaux acteurs du marché	Novartis AG Johnson &amp Johnson Private Limited Teva Pharmaceutical Industries Ltd. Merck &amp Co.Inc. Allergan Pfizer Inc. GlaxoSmithKline plc Sanofi Merck KGaA Abbott Boehringer Ingelheim International GmbH. Takeda Pharmaceutical Company Limited Amicus TherapeuticsInc. ModernaInc. Greenovation Biotech GmbH Biomarin JCR Pharmaceuticals Co.Ltd ISU ABXIS Idorsia Pharmaceuticals Ltd AVROBIOInc. Resverlogix Corp. Enzyvant CHIESI Farmaceutici SpA

Global Lysosomal Storage Disorder Drugs Market Segmentation, By Type of Disorder Gaucher DiseaseFabry DiseasePompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick DiseaseKrabbe Disease, and Others), Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others), Drugs (Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others), Route of Administration (Intravenous (IV), Subcutaneous (SC), Oral, and Others), Age Group (Pediatric, Adults, and Geriatric), Gender (Male and Female), Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032

Lysosomal Storage Disorder Drugs Market Analysis

The global lysosomal storage disorder drugs market encompasses the commercial sector for pharmaceuticals developed to diagnose, treat, and manage various lysosomal storage disorders, which are rare genetic conditions typically characterized by the accumulation of undigested substances within lysosomes due to enzyme deficiencies. This market includes a range of therapeutic products, such as enzyme replacement therapies, substrate reduction therapies, and gene therapies, aimed at addressing the diverse clinical manifestations of LSDs, such as Gaucher disease, Fabry disease, and Pompe disease. With increasing awareness, advancements in research and technology, and a growing number of pipeline therapies, this market is poised for significant expansion. In addition, rising healthcare expenditure and initiatives to improve access to rare disease treatments further drive market growth, presenting both opportunities and challenges for pharmaceutical companies and healthcare providers.

Lysosomal Storage Disorder Drugs Market Size

Global lysosomal storage disorder drugs market size was valued at USD 10.76 billion in 2024 and is projected to reach USD 21.93 billion by 2032, growing with a CAGR of 9.4% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Lysosomal Storage Disorder Drugs Market Trends

“Biotechnology Advancements for Lysosomal Storage Disorders Treatments”

Advancements in biotechnology have played a pivotal role in transforming the treatment landscape for Lysosomal Storage Disorders (LSDs), providing patients with more effective and tailored treatment options. Enzyme Replacement Therapy (ERT) has revolutionized the treatment of Lysosomal Storage Disorders (LSDs) by directly addressing the enzyme deficiencies that cause these conditions. In LSD patients, the lack of specific enzymes leads to the accumulation of toxic substances in cells, damaging organs and tissues. ERT works by administering synthetic enzymes to compensate for the missing ones, improving metabolic functions and alleviating symptoms. Over the years, ERT has advanced significantly, with new, more effective formulations and delivery methods that improve enzyme absorption and reduce side effects. These innovations have resulted in better clinical outcomes, this trend slowed disease progression, reduced organ damage, and enhanced patient quality of life.

Report Scope and Lysosomal Storage Disorder Drugs Market Segmentation

Attributes	Lysosomal Storage Disorder Drugs Key Market Insights
Segments Covered	By Type of Disorder: Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Krabbe Disease, and Others By Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others By Drugs: Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others By Route of Administration: Intravenous (IV), Subcutaneous (SC), Oral, and Others By Age Group: Pediatric, Adults, and Geriatric By Gender: Male and Female By Distribution Channel: Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies
Countries Covered	U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Denmark, Sweden, Poland, Norway, Finland, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Qatar, Saudi Arabia, and rest of Middle East and Africa
Key Market Players	Sanofi (France), BioMarin (U.S.), Pfizer Inc. (U.S.), Amicus Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Ultragenyx Pharmaceutical Inc. (U.S.), Orchard Therapeutics plc (U.K.), Spur Therapeutics (U.K.), Sangamo Therapeutics (U.S.), Protalix BioTherapeutics Inc. (Israel), CHIESI Farmaceutici S.p.A. (Italy), Forge Biologics (U.S.), Denali Therapeutics (U.S.), REGENXBIO INC. (U.S.), and JCR Pharmaceuticals Co., Ltd. (Japan) among others
Market Opportunities	Increasing Number of Pipeline Drugs Growing Emphasis on Early Diagnosis
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Lysosomal Storage Disorder Drugs Market Definition

Lysosomal storage disorder drugs refer to a category of pharmaceuticals specifically developed to treat Lysosomal Storage Disorders (LSDs), which are a group of rare genetic conditions caused by deficiencies in specific enzymes responsible for breaking down complex molecules within lysosomes. These drugs aim to address the underlying metabolic abnormalities associated with LSDs by either replacing the missing enzymes (enzyme replacement therapy), by enhancing the body's ability to produce the enzymes, or by modifying the substrates that accumulate due to enzyme deficiency (substrate reduction therapy). By improving enzymatic function or reducing the toxic build-up of substrates, these treatments can alleviate symptoms, slow disease progression, and ultimately improve the quality of life for individuals affected by these challenging conditions.

Lysosomal Storage Disorder Drugs Market Dynamics

Drivers

Emerging Personalized Medicine for Lysosomal Storage Disorders

Emerging personalized medicine is transforming the landscape of treatment for Lysosomal Storage Disorders (LSDs) by offering therapies specifically tailored to the individual genetic profiles of patients. LSDs are caused by genetic mutations that affect enzyme function, and these mutations can vary widely between patients. Personalized treatments involve analyzing a patient’s unique genetic makeup to develop a more targeted approach, optimizing the efficacy of therapies such as enzyme replacement or gene therapy. This precision allows for better matching of treatments with the patient's specific needs, minimizing side effects and enhancing therapeutic outcomes. As advancements in genetic testing and technology progress, healthcare providers are able to identify the most suitable interventions, potentially improving response rates and overall treatment success. The shift toward personalized medicine is accelerating the development of customized LSD treatments, which promise to revolutionize disease management. With these innovations, the global lysosomal storage disorders drug market is witnessing increased demand for more effective, individualized treatment options. Personalized medicine is thus a key driver of market growth, as it boosts treatment effectiveness and enhances patient outcomes, fostering greater confidence in therapeutic options.

For instance,

In February 2023, according to the article published by NCBI, Emerging personalized medicine uses an individual’s genetic profile to guide decisions related to the prevention, diagnosis, and treatment of diseases. This approach enables more precise and effective therapies for Lysosomal Storage Disorders (LSDs), tailoring treatments to specific genetic mutations. As personalized medicine becomes more prevalent, it drives the demand for targeted LSD therapies, fueling growth in the global lysosomal storage disorders drug market.

Increased Government Funding for Research into Rare Disease Treatments

Les subventions et le financement publics pour la recherche sur les traitements des maladies rares sont essentiels pour faire progresser le développement de thérapies pour des maladies telles que les troubles de stockage lysosomal (LSD). Les maladies rares, souvent dépourvues de viabilité commerciale en raison de la petite population de patients, posent des défis importants pour le développement de médicaments. Pour y remédier, les gouvernements du monde entier allouent de plus en plus de fonds pour encourager la recherche dans ces domaines mal desservis. Le soutien financier sous forme de subventions, de subventions et de crédits d’impôt aide les sociétés pharmaceutiques et les institutions de recherche à surmonter les coûts et les risques élevés associés au développement de traitements pour les maladies rares. En outre, les gouvernements accélèrent souvent les processus réglementaires pour ces traitements, reconnaissant le besoin urgent de solutions. En réduisant la charge financière pesant sur les chercheurs et les entreprises, ces mécanismes de financement permettent l’exploration de thérapies innovantes, telles que le remplacement enzymatique et les thérapies géniques, qui seraient autrement confrontées à des obstacles importants au développement.

Par exemple,

En août 2023, selon l'article publié par la National Organization for Rare Diseases, la National Organization for Rare Disorders a annoncé un financement de plus de 100 000 USD en subventions pour la recherche sur les maladies rares, soulignant ainsi le soutien accru du gouvernement à l'avancement des traitements. Ces fonds permettent aux chercheurs d'explorer des thérapies innovantes pour les maladies rares comme les troubles de stockage lysosomal (LSD). Un tel soutien financier accélère le développement de médicaments, stimulant la croissance du marché mondial des médicaments à base de LSD en favorisant de nouvelles options de traitement.

Opportunités

Augmentation du nombre de médicaments en développement

Le nombre croissant de médicaments en cours de développement pour les troubles de stockage lysosomal (TSL) représente une opportunité significative pour le marché mondial des médicaments contre les TLS, ce qui pourrait conduire à de meilleures options de traitement et à de meilleurs résultats pour les patients. À mesure que les chercheurs et les sociétés pharmaceutiques améliorent leur compréhension de ces troubles, ils développent un large éventail de nouvelles thérapies, notamment des thérapies géniques, des thérapies de réduction de substrat et des médicaments à base de petites molécules. Ce pipeline élargi reflète une reconnaissance croissante des besoins médicaux non satisfaits au sein de la communauté des TLS et promet d'offrir aux patients une plus grande variété de modalités de traitement adaptées à leurs conditions spécifiques. L'introduction de thérapies innovantes peut améliorer l'observance du traitement par les patients, réduire la charge de morbidité et, en fin de compte, améliorer la qualité de vie des personnes atteintes de ces troubles.

Par exemple,

En juin 2024, Ultragenyx a annoncé son intention de déposer une demande d'approbation accélérée pour l'UX111 pour le traitement du syndrome de Sanfilippo de type A (MPS IIIA). L'UX111 est une nouvelle thérapie génique in vivo en phase 1/2/3 de développement pour le syndrome de Sanfilippo de type A (MPS IIIA), une maladie lysosomale mortelle rare sans traitement approuvé qui affecte principalement le système nerveux central.

Importance croissante accordée au diagnostic précoce

L’importance croissante accordée au diagnostic précoce des troubles de stockage lysosomal (TSL) présente une opportunité significative pour le marché mondial des médicaments contre les TLS en facilitant des interventions opportunes qui peuvent grandement améliorer les résultats des patients. Alors que les systèmes de santé accordent une plus grande importance à la détection précoce grâce à des programmes de dépistage améliorés, des tests génétiques et des avancées dans les technologies de diagnostic, davantage de patients sont susceptibles d’être diagnostiqués à un stade plus précoce de leur maladie. Cette intervention précoce permet une meilleure gestion des symptômes mais augmente l’efficacité potentielle des thérapies existantes et émergentes. Le résultat de ce changement est une base de patients plus large qui nécessite et peut bénéficier d’options de traitement, ce qui stimule finalement la demande sur le marché des médicaments contre les TLS.

Par exemple,

En février 2023, selon un article intitulé « Troubles de stockage lysosomal : de la biologie à la clinique en référence à l'Inde », le diagnostic précoce est la partie la plus critique de la gestion des LSD car il offre la possibilité d'une intervention thérapeutique, d'un conseil génétique précis, d'un diagnostic prénatal et d'un meilleur résultat pour le patient.

Contraintes/Défis

Manque de sensibilisation des professionnels de la santé et des patients

Le manque de sensibilisation des professionnels de santé et des patients aux troubles de stockage lysosomal (TSL) constitue un obstacle important au diagnostic précoce, au traitement et à la gestion efficace. De nombreux prestataires de soins de santé, en particulier dans les régions où l'exposition aux maladies rares est limitée, ne parviennent souvent pas à reconnaître les symptômes des TSL, qui sont divers et se chevauchent avec d'autres affections plus courantes. Ce manque de connaissances entraîne des diagnostics tardifs, des erreurs de diagnostic et un traitement inefficace, ce qui aggrave la gravité de la maladie. Pour les patients, en particulier ceux qui vivent dans des zones pauvres en ressources ou mal desservies, le manque de sensibilisation empêche une intervention précoce, les laissant dans l'ignorance des thérapies potentielles. La complexité et la rareté des TSL compliquent encore davantage la situation, car les patients et les professionnels de santé peuvent ne pas comprendre pleinement l'importance d'un traitement précoce ou la disponibilité d'options de soins spécialisées. Moins de patients sont diagnostiqués et traités à temps, ce qui entraîne des résultats cliniques sous-optimaux. Ce manque de sensibilisation limite la demande de traitements spécifiques au TSL et freine la croissance globale du marché mondial des médicaments contre les troubles de stockage lysosomal.

Par exemple,

En janvier 2024, selon l'article publié par Wiley, il existe un retard diagnostique important d'environ 15 ans entre l'apparition des symptômes et le diagnostic dans les cas de LSD chez l'adulte en raison du chevauchement des phénotypes cliniques et de la gravité variable. Ce retard met en évidence le manque de sensibilisation des professionnels de la santé, en particulier ceux qui traitent des patients adultes. De telles contraintes entravent la détection précoce et le traitement rapide, limitant ainsi la croissance du marché mondial des médicaments contre les troubles de stockage lysosomal.

Procédures d'approbation de médicaments prolongées

Les longs processus d’approbation des médicaments constituent un frein important pour le marché mondial des médicaments contre les troubles de stockage lysosomal, ralentissant l’introduction de thérapies indispensables. Le processus d’obtention d’une approbation réglementaire pour de nouveaux médicaments, en particulier pour les maladies rares comme les LSD, implique de nombreux essais cliniques, une documentation approfondie et des évaluations rigoureuses par des organismes de réglementation tels que la FDA et l’EMA. Ces délais d’approbation sont souvent prolongés en raison de la nécessité d’une évaluation approfondie de la sécurité, de l’efficacité et des effets potentiels à long terme. Dans le cas des LSD, la rareté et la complexité de ces maladies ajoutent un autre niveau de défi, car la population de patients pour les essais cliniques est limitée, ce qui rend difficile la génération de données fiables. Le besoin de traitements spécialisés et l’absence de normes établies pour ces maladies rares compliquent le processus d’approbation. Par conséquent, les développeurs de médicaments sont confrontés à des périodes d’attente prolongées, à des retards dans la mise sur le marché de nouveaux traitements et à des coûts supplémentaires, ce qui peut être décourageant pour les sociétés pharmaceutiques. En conséquence, les longs processus d’approbation ralentissent la disponibilité de thérapies innovantes pour les patients, réduisant la croissance du marché et entravant l’accessibilité à des traitements efficaces pour les LSD. Ce retard réglementaire constitue en fin de compte un frein majeur pour le marché mondial des médicaments contre les troubles de stockage lysosomal.

Par exemple,

En août 2024, selon l’article publié par Drugs.com, le processus de recherche, de développement et d’approbation des médicaments prend généralement entre 12 et 15 ans. Ce délai prolongé retarde l’introduction de nouvelles thérapies et augmente les coûts pour les sociétés pharmaceutiques. En conséquence, le long processus d’approbation des médicaments freine la croissance du marché mondial des médicaments à base de LSD en limitant la rapidité de la disponibilité des traitements.

Ce rapport de marché fournit des détails sur les nouveaux développements récents, les réglementations commerciales, l'analyse des importations et des exportations, l'analyse de la production, l'optimisation de la chaîne de valeur, la part de marché, l'impact des acteurs du marché national et local, les opportunités d'analyse en termes de poches de revenus émergentes, les changements dans la réglementation du marché, l'analyse stratégique de la croissance du marché, la taille du marché, la croissance des catégories de marché, les niches d'application et la domination, les approbations de produits, les lancements de produits, les expansions géographiques, les innovations technologiques sur le marché. Pour obtenir plus d'informations sur le marché, contactez Data Bridge Market Research pour un briefing d'analyste, notre équipe vous aidera à prendre une décision de marché éclairée pour atteindre la croissance du marché.

Portée du marché des médicaments contre les troubles du stockage lysosomal

Le marché est segmenté en fonction du type de trouble, du type, des médicaments, de la voie d'administration, de la tranche d'âge, du sexe et du canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance faibles dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.

Type de trouble

Maladie de Gaucher
- Type 1
- Type 3
- Type 2
Maladie de Fabry
Maladie de Pompe
- Pompe à début infantile
- Maladie de Pompe à début tardif
Mucopolysaccharidose (MPS)
- MPS I
- MPS II
- MPS IV
- MPS VI
- MPS III
Maladie de Niemann-Pick
- Type C
- Type B
- Type A
Maladie de Krabbe
Autres

Taper

Thérapie de remplacement enzymatique (ERT)
Thérapie de réduction du substrat (SRT)
Thérapie d'accompagnement
Autres

Médicaments

Imiglucérase
Agalsidase bêta
Idursulfase
Alglucosidase alpha
Vélaglucérase
Taliglucérase Alfa
Laronidase
Agalsidase alpha
Galsulfase
Avalglucosidase alpha
Autres

Voie d'administration

Intraveineuse (IV)
Sous-cutané (SC)
Oral
Autres

Groupe d'âge

Pédiatrique
Adultes
Gériatrie

Genre

Mâle
Femelle

Canal de distribution

Pharmacies hospitalières
Pharmacies de détail et magasins de médicaments
Pharmacies en ligne

Analyse régionale du marché des médicaments contre les troubles du stockage lysosomal

Le marché est analysé et des informations sur la taille du marché et les tendances sont fournies par type de trouble, type, médicaments, voie d'administration, groupe d'âge, sexe et canal de distribution comme référencé ci-dessus.

Les pays couverts sur le marché sont les États-Unis, le Canada, le Mexique, l'Allemagne, le Royaume-Uni, l'Italie, la France, l'Espagne, la Russie, la Suisse, la Turquie, la Belgique, les Pays-Bas, le Danemark, la Suède, la Pologne, la Norvège, la Finlande, le reste de l'Europe, le Japon, la Chine, la Corée du Sud, l'Inde, Singapour, la Thaïlande, l'Indonésie, la Malaisie, les Philippines, l'Australie, la Nouvelle-Zélande, le Vietnam, Taiwan, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Égypte, Bahreïn, les Émirats arabes unis, le Koweït, Oman, le Qatar, l'Arabie saoudite et le reste du Moyen-Orient et de l'Afrique.

L’Amérique du Nord devrait dominer le marché mondial des médicaments contre les troubles de stockage lysosomal en raison de son infrastructure de soins de santé avancée, de son adoption élevée de médicaments, de ses investissements importants en recherche et développement et d’une large population de patients.

L’Asie-Pacifique devrait connaître la croissance la plus rapide en raison de l’amélioration des infrastructures de soins de santé, de la prévalence croissante des maladies de stockage lysosomales et de la sensibilisation croissante aux thérapies avancées.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Part de marché des médicaments contre les troubles de stockage lysosomal

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Lysosomal Storage Disorder Drugs Market Leaders Operating in the Market Are:

Sanofi (France)
BioMarin (U.S.)
Pfizer Inc. (U.S.)
Amicus Therapeutics, Inc. (U.S.)
Takeda Pharmaceutical Company Limited (Japan)
Ultragenyx Pharmaceutical Inc. (U.S.)
Orchard Therapeutics plc (U.K.)
Spur Therapeutics (U.K.)
Sangamo Therapeutics (U.S.)
Protalix BioTherapeutics Inc. (Israel)
Chiesi Farmaceutici S.p.A. (Italy)
Forge Biologics (U.S.)
Denali Therapeutics (U.S.)
REGENXBIO INC. (U.S.)
JCR Pharmaceuticals Co., Ltd. (Japan)

Latest Developments in Lysosomal Storage Disorder Drugs Market

In October 2024, Amicus Therapeutics announced a settlement regarding its drug Galafold (migalastat), which treats Fabry disease. The settlement resolves ongoing patent disputes and confirms the continuation of the drug’s marketing without litigation interference. This agreement with multiple parties aims to provide stability for Galafold’s availability and development while protecting intellectual property rights
In June 2024, Amicus Therapeutics was honored with the Prix Galien UK Award for its innovative treatment, Pombiliti (miglustat), for the management of Fabry disease. The award recognizes excellence in pharmaceutical innovation and emphasizes the impact of Pombiliti in improving the lives of patients with rare genetic conditions. This accolade highlights Amicus’ leadership in rare disease therapies
In April 2024, Forge Biologics announced it would present nine times at the ASGCT 27th Annual Meeting in May 2024, including a late-breaking oral presentation and three technical sessions. Presentations will cover process development, molecular advancements, and clinical updates, including a significant clinical result for FBX-101 in Krabbe disease
In November 2023, Chiesi Group has been reaccredited as a Great Place to Work-Certified organization across multiple regions, including Italy, Australia, the US, and others. With an 85% response rate from employees, Chiesi achieved an 83% overall satisfaction rate, reflecting its commitment to fostering a positive, inclusive, and collaborative work environment focused on employee well-being and growth
En janvier 2024, Denali Therapeutics Inc., une société biopharmaceutique qui développe des thérapies permettant de traverser la barrière hémato-encéphalique pour traiter les maladies neurodégénératives et de stockage lysosomal, a annoncé des progrès et des jalons pour 2024. Le PDG Ryan Watts, Ph.D., a souligné ces développements lors d'une présentation d'entreprise lors de la 42e conférence annuelle JP Morgan Healthcare le 9 janvier

SKU-59872

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Cliquez sur l'image pour l'agrandir

Tableau de bord d'analyse de données interactif
Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
Accès d'analyste de recherche pour la personnalisation et les requêtes
Analyse de la concurrence avec tableau de bord interactif
Dernières actualités, mises à jour et analyse des tendances
Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence

Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PIPELINE ANALYSIS

5 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN NORTH AMERICA

5.2 REGULATORY AUTHORITIES IN SOUTH AMERICA

5.3 REGULATORY AUTHORITIES IN EUROPE

5.4 REGULATORY AUTHORITIES IN THE MIDDLE EAST AND AFRICA.

5.5 REGULATORY AUTHORITIES IN ASIA-PACIFIC.

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDERS TREATMENTS

6.1.2 EMERGING PERSONALIZED MEDICINE FOR LYSOSOMAL STORAGE DISORDERS

6.1.3 INCREASED GOVERNMENT FUNDING FOR RESEARCH INTO RARE DISEASE TREATMENTS

6.1.4 COLLABORATIONS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTIONS

6.2 RESTRAINTS

6.2.1 LACK OF AWARENESS AMONG HEALTHCARE PROFESSIONALS AND PATIENTS

6.2.2 PROLONGED DRUG APPROVAL PROCEDURES

6.3 OPPORTUNITIES

6.3.1 INCREASING NUMBER OF PIPELINE DRUGS

6.3.2 GROWING EMPHASIS ON EARLY DIAGNOSIS

6.3.3 ADVANCEMENTS IN GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS

6.4 CHALLENGES

6.4.1 SIGNIFICANT EXPENSES RELATED TO THE TREATMENT OF THE DISEASE

6.4.2 NARROW PATIENT BASE SUFFERING FROM LYSOSOMAL STORAGE DISORDERS

7 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

7.1 OVERVIEW

7.2 GAUCHER DISEASE

7.2.1 TYPE 1

7.2.2 TYPE 3

7.2.3 TYPE 2

7.3 FABRY DISEASE

7.4 POMPE DISEASE

7.4.1 INFANTILE-ONSET POMPE

7.4.2 LATE-ONSET POMPE

7.5 MUCOPOLYSACCHARIDOSIS (MPS)

7.5.1 MPS I

7.5.2 MPS II

7.5.3 MPS IV

7.5.4 MPS VI

7.5.5 MPS III

7.6 NIEMANN-PICK DISEASE

7.6.1 TYPE C

7.6.2 TYPE B

7.6.3 TYPE A

7.7 KRABBE DISEASE

7.8 OTHERS

8 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS

8.1 OVERVIEW

8.2 IMIGLUCERASE

8.3 AGALSIDASE BETA

8.4 IDURSULFASE

8.5 ALGLUCOSIDASE ALPHA

8.6 VELAGLUCERASE

8.7 TALIGLUCERASE ALFA

8.8 LARONIDASE

8.9 AGALSIDASE ALPHA

8.1 GALSULFASE

8.11 AVALGLUCOSIDASE ALFA

8.12 OTHERS

9 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE

9.1 OVERVIEW

9.2 ENZYME REPLACEMENT THERAPY (ERT)

9.3 SUBSTRATE REDUCTION THERAPY (SRT)

9.4 CHAPERONE THERAPY

9.5 OTHERS

10 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.3 FEMALE

11 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 PEDIATRIC

11.3 ADULT

11.4 GERIATRIC

12 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 DRUGS STORES AND RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 INTRAVENOUS (IV)

13.3 SUBCUTANEOUS (SC)

13.4 ORAL

13.5 OTHERS

14 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 UNITED KINGDOM

14.3.3 FRANCE

14.3.4 ITALY

14.3.5 SPAIN

14.3.6 RUSSIA

14.3.7 SWITZERLAND

14.3.8 TURKEY

14.3.9 BELGIUM

14.3.10 NETHERLANDS

14.3.11 DENMARK

14.3.12 SWEDEN

14.3.13 POLAND

14.3.14 NORWAY

14.3.15 FINLAND

14.3.16 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 JAPAN

14.4.3 INDIA

14.4.4 SOUTH KOREA

14.4.5 AUSTRALIA

14.4.6 THAILAND

14.4.7 SINGAPORE

14.4.8 INDONESIA

14.4.9 MALAYSIA

14.4.10 PHILIPPINES

14.4.11 TAIWAN

14.4.12 NEW ZEALAND

14.4.13 VIETNAM

14.4.14 REST OF ASIA-PACIFIC

14.5 MIDDLE EAST AND AFRICA

14.5.1 SAUDI ARABIA

14.5.2 UNITED ARAB EMIRATES (UAE)

14.5.3 SOUTH AFRICA

14.5.4 EGYPT

14.5.5 QATAR

14.5.6 KUWAIT

14.5.7 OMAN

14.5.8 BAHRAIN

14.5.9 REST OF MIDDLE EAST AND AFRICA

14.6 SOUTH AMERICA

14.6.1 BRAZIL

14.6.2 ARGENTINA

14.6.3 REST OF SOUTH AMERICA

15 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 SANOFI

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 BIOMARIN

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 PFIZER INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 AMICUS THERAPEUTIC, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 CHIESI FARMACEUTICI S.P.A.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 DENALI THERAPEUTICS

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PIPELINE PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 FORGE BIOLOGICS

17.8.1 COMPANY SNAPSHOT

17.8.2 PIPELINE PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 JCR PHARMACEUTICALS CO., LTD.

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PINELINE PRODUCT PORTFOLIO

17.9.4 PRODUCT PORTFOLIO

17.9.5 RECENT DEVELOPMENT

17.1 ORCHARD THERAPEUTICS PLC

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 PROTALIX BIOTHERAPEUTICS

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PIPELINE PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 REGENXBIO INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PINELINE PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 SANGAMO THERAPEUTICS

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 SPUR THERAPEUTICS

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 ULTRAGENYX PHARMACEUTICAL INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Liste des tableaux

TABLE 1 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 2 GLOBAL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 3 GLOBAL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 4 GLOBAL FABRY DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 5 GLOBAL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 6 GLOBAL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 7 GLOBAL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 8 GLOBAL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 9 GLOBAL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 10 GLOBAL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 11 GLOBAL KRABBE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 12 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 13 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 14 GLOBAL IMIGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 15 GLOBAL AGALSIDASE BETA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 16 GLOBAL IDURSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 17 GLOBAL ALGLUCOSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 18 GLOBAL VELAGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 19 GLOBAL TALIGLUCERASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 20 GLOBAL LARONIDASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 21 GLOBAL AGALSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 22 GLOBAL GALSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 23 GLOBAL AVALGLUCOSIDASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 24 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 25 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 26 GLOBAL ENZYME REPLACEMENT THERAPY (ERT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 27 GLOBAL SUBSTRATE REDUCTION THERAPY (SRT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 28 GLOBAL CHAPERONE THERAPY IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 29 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 30 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 31 GLOBAL MALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 32 GLOBAL FEMALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 33 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 34 GLOBAL PEDIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 35 GLOBAL ADULT IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 36 GLOBAL GERIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 37 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 38 GLOBAL HOSPITAL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 39 GLOBAL DRUGS STORES AND RETAIL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 40 GLOBAL ONLINE PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 41 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 42 GLOBAL INTRAVENOUS (IV) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 43 GLOBAL SUBCUTANEOUS (SC) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 44 GLOBAL ORAL IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 45 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 46 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 47 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 48 NORTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 49 NORTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 50 NORTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 51 NORTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 52 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 53 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 54 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 55 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 56 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 57 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 58 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 59 U.S. GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 60 U.S. POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 61 U.S. MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 62 U.S. NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 63 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 64 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 65 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 66 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 67 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 68 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 69 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 70 CANADA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 71 CANADA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 72 CANADA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 73 CANADA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 74 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 75 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 76 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 77 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 78 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 79 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 80 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 81 MEXICO GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 82 MEXICO POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 83 MEXICO MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 84 MEXICO NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 85 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 86 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 87 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 88 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 89 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 90 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 91 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 92 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 93 EUROPE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 94 EUROPE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 95 EUROPE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 96 EUROPE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 97 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 98 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 99 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 100 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 101 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 102 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 103 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 104 GERMANY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 105 GERMANY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 106 GERMANY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 107 GERMANY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 108 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 109 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 110 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 111 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 112 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 113 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 114 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 115 UNITED KINGDOM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 116 UNITED KINGDOM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 117 UNITED KINGDOM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 118 UNITED KINGDOM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 119 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 120 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 121 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 122 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 123 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 124 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 125 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 126 FRANCE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 127 FRANCE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 128 FRANCE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 129 FRANCE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 130 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 131 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 132 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 133 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 134 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 135 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 136 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 137 ITALY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 138 ITALY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 139 ITALY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 140 ITALY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 141 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 142 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 143 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 144 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 145 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 146 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 147 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 148 SPAIN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 149 SPAIN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 150 SPAIN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 151 SPAIN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 152 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 153 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 154 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 155 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 156 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 157 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 158 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 159 RUSSIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 160 RUSSIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 161 RUSSIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 162 RUSSIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 163 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 164 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 165 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 166 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 167 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 168 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 169 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 170 SWITZERLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 171 SWITZERLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 172 SWITZERLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 173 SWITZERLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 174 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 175 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 176 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 177 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 178 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 179 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 180 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 181 TURKEY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 182 TURKEY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 183 TURKEY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 184 TURKEY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 185 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 186 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 187 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 188 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 189 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 190 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 191 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 192 BELGIUM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 193 BELGIUM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 194 BELGIUM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 195 BELGIUM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 196 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 197 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 198 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 199 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 200 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 201 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 202 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 203 NETHERLANDS GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 204 NETHERLANDS POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 205 NETHERLANDS MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 206 NETHERLANDS NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 207 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 208 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 209 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 210 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 211 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 212 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 213 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 214 DENMARK GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 215 DENMARK POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 216 DENMARK MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 217 DENMARK NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 218 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 219 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 220 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 221 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 222 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 223 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 224 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 225 SWEDEN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 226 SWEDEN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 227 SWEDEN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 228 SWEDEN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 229 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 230 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 231 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 232 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 233 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 234 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 235 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 236 POLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 237 POLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 238 POLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 239 POLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 240 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 241 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 242 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 243 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 244 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 245 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 246 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 247 NORWAY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 248 NORWAY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 249 NORWAY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 250 NORWAY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 251 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 252 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 253 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 254 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 255 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 256 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 257 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 258 FINLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 259 FINLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 260 FINLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 261 FINLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 262 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 263 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 264 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 265 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 266 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 267 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 268 REST OF EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 269 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 270 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 271 ASIA-PACIFIC GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 272 ASIA-PACIFIC POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 273 ASIA-PACIFIC MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 274 ASIA-PACIFIC NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 275 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 276 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 277 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 278 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 279 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 280 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 281 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 282 CHINA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 283 CHINA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 284 CHINA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 285 CHINA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 286 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 287 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 288 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 289 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 290 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 291 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 292 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 293 JAPAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 294 JAPAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 295 JAPAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 296 JAPAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 297 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 298 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 299 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 300 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 301 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 302 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 303 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 304 INDIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 305 INDIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 306 INDIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 307 INDIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 308 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 309 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 310 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 311 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 312 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 313 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 314 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 315 SOUTH KOREA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 316 SOUTH KOREA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 317 SOUTH KOREA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 318 SOUTH KOREA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 319 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 320 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 321 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 322 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 323 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 324 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 325 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 326 AUSTRALIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 327 AUSTRALIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 328 AUSTRALIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 329 AUSTRALIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 330 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 331 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 332 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 333 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 334 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 335 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 336 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 337 THAILAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 338 THAILAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 339 THAILAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 340 THAILAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 341 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 342 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 343 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 344 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 345 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 346 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 347 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 348 SINGAPORE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 349 SINGAPORE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 350 SINGAPORE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 351 SINGAPORE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 352 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 353 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 354 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 355 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 356 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 357 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 358 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 359 INDONESIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 360 INDONESIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 361 INDONESIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 362 INDONESIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 363 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 364 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 365 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 366 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 367 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 368 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 369 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 370 MALAYSIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 371 MALAYSIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 372 MALAYSIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 373 MALAYSIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 374 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 375 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 376 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 377 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 378 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 379 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 380 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 381 PHILIPPINES GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 382 PHILIPPINES POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 383 PHILIPPINES MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 384 PHILIPPINES NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 385 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 386 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 387 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 388 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 389 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 390 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 391 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 392 TAIWAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 393 TAIWAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 394 TAIWAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 395 TAIWAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 396 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 397 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 398 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 399 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 400 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 401 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 402 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 403 NEW ZEALAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 404 NEW ZEALAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 405 NEW ZEALAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 406 NEW ZEALAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 407 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 408 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 409 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 410 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 411 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 412 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 413 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 414 VIETNAM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 415 VIETNAM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 416 VIETNAM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 417 VIETNAM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 418 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 419 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 420 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 421 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 422 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 423 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 424 REST OF ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 425 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 426 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 427 MIDDLE EAST AND AFRICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 428 MIDDLE EAST AND AFRICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 429 MIDDLE EAST AND AFRICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 430 MIDDLE EAST AND AFRICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 431 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 432 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 433 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 434 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 435 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 436 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 437 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 438 SAUDI ARABIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 439 SAUDI ARABIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 440 SAUDI ARABIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 441 SAUDI ARABIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 442 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 443 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 444 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 445 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 446 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 447 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 448 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 449 UNITED ARAB EMIRATES (UAE) GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 450 UNITED ARAB EMIRATES (UAE) POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 451 UNITED ARAB EMIRATES (UAE) MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 452 UNITED ARAB EMIRATES (UAE) NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 453 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 454 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 455 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 456 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 457 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 458 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 459 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 460 SOUTH AFRICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 461 SOUTH AFRICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 462 SOUTH AFRICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 463 SOUTH AFRICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 464 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 465 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 466 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 467 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 468 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 469 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 470 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 471 EGYPT GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 472 EGYPT POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 473 EGYPT MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 474 EGYPT NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 475 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 476 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 477 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 478 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 479 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 480 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 481 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 482 QATAR GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 483 QATAR POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 484 QATAR MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 485 QATAR NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 486 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 487 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 488 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 489 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 490 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 491 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 492 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 493 KUWAIT GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 494 KUWAIT POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 495 KUWAIT MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 496 KUWAIT NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 497 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 498 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 499 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 500 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 501 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 502 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 503 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 504 OMAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 505 OMAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 506 OMAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 507 OMAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 508 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 509 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 510 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 511 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 512 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 513 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 514 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 515 BAHRAIN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 516 BAHRAIN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 517 BAHRAIN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 518 BAHRAIN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 519 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 520 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 521 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 522 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 523 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 524 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 525 REST OF MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 526 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 527 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 528 SOUTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 529 SOUTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 530 SOUTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 531 SOUTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 532 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 533 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 534 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 535 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 536 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 537 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 538 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 539 BRAZIL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 540 BRAZIL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 541 BRAZIL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 542 BRAZIL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 543 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 544 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 545 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 546 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 547 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 548 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 549 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 550 ARGENTINA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 551 ARGENTINA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 552 ARGENTINA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 553 ARGENTINA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 554 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 555 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 556 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 557 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 558 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 559 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 560 REST OF SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

Liste des figures

FIGURE 1 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 2 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 SEVEN SEGMENTS COMPRISE THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LYSOSOMAL STORAGE DISORDER MARKET AND ASIA PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDER TREATMENTS IS EXPECTED TO DRIVE THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 15 GAUCHER DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN 2025 & 2032

FIGURE 16 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

FIGURE 17 PESTEL ANALYSIS

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

FIGURE 19 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2024

FIGURE 20 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2025-2032 (USD MILLION)

FIGURE 21 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, CAGR (2025-2032)

FIGURE 22 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, LIFELINE CURVE

FIGURE 23 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2024

FIGURE 24 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2025-2032 (USD MILLION)

FIGURE 25 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, CAGR (2025-2032)

FIGURE 26 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 27 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2024

FIGURE 28 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2025-2032 (USD MILLION)

FIGURE 29 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 30 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 31 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2024

FIGURE 32 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2025-2032 (USD MILLION)

FIGURE 33 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 34 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 35 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2024

FIGURE 36 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2025-2032 (USD MILLION)

FIGURE 37 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 38 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 39 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 40 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

FIGURE 41 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 42 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 44 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)

FIGURE 45 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 46 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 47 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SNAPSHOT 2024

FIGURE 48 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 49 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 50 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 51 AISA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

Voir les informations détaillées

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

Quels sont les principaux segments couverts dans le rapport Global Lysosomal Storage Disorder Drugs Market ?

Le marché est segmenté en fonction de Segmentation, By Type of Disorder Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Krabbe Disease, and Others), Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others), Drugs (Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others), Route of Administration (Intravenous (IV), Subcutaneous (SC), Oral, and Others), Age Group (Pediatric, Adults, and Geriatric), Gender (Male and Female), Distribution Channel  (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032 .

Quelle est la taille actuelle du marché de Global Lysosomal Storage Disorder Drugs Market ?

La taille du Global Lysosomal Storage Disorder Drugs Market était estimée à 10.76 USD Billion USD en 2024.

Quel est le taux de croissance prévu du Global Lysosomal Storage Disorder Drugs Market ?

Le Global Lysosomal Storage Disorder Drugs Market devrait croître à un TCAC de 9.4% sur la période de prévision de 2025 à 2032.

Qui sont les principaux acteurs du Global Lysosomal Storage Disorder Drugs Market ?

Les principaux acteurs du marché sont ,Novartis AG Johnson &amp, Johnson Private Limited Teva Pharmaceutical Industries Ltd. Merck &amp, Co.Inc. Allergan Pfizer Inc. GlaxoSmithKline plc Sanofi Merck KGaA Abbott Boehringer Ingelheim International GmbH. Takeda Pharmaceutical Company Limited Amicus TherapeuticsInc. ModernaInc. Greenovation Biotech GmbH Biomarin JCR Pharmaceuticals Co.Ltd ISU ABXIS Idorsia Pharmaceuticals Ltd AVROBIOInc. Resverlogix Corp. Enzyvant CHIESI Farmaceutici SpA ,.

Quels pays sont analysés dans le rapport Global Lysosomal Storage Disorder Drugs Market ?

Le rapport couvre les données de U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Denmark, Sweden, Poland, Norway, Finland, rest of Europe, Japan, China, South Korea,  India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Qatar, Saudi Arabia, and rest of Middle East and Africa.

Global Lysosomal Storage Disorder Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Contournez les défis liés aux tarifs grâce à un conseil agile en chaîne d'approvisionnement

Global Lysosomal Storage Disorder Drugs Market

TCAC : 9.40 %

Lysosomal Storage Disorder Drugs Market Analysis

Lysosomal Storage Disorder Drugs Market Size

Portée du marché des médicaments contre les troubles du stockage lysosomal

Analyse régionale du marché des médicaments contre les troubles du stockage lysosomal

Part de marché des médicaments contre les troubles de stockage lysosomal

Latest Developments in Lysosomal Storage Disorder Drugs Market

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Table des matières

Liste des tableaux

Liste des figures

Méthodologie de recherche

Personnalisation disponible

Questions fréquemment posées

Rapports

Aperçus du marché

Soutien

Solutions

Global Lysosomal Storage Disorder Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Contournez les défis liés aux tarifs grâce à un conseil agile en chaîne d'approvisionnement

Global Lysosomal Storage Disorder Drugs Market

TCAC : 9.40 %

Lysosomal Storage Disorder Drugs Market Analysis

Lysosomal Storage Disorder Drugs Market Size

Portée du marché des médicaments contre les troubles du stockage lysosomal

Analyse régionale du marché des médicaments contre les troubles du stockage lysosomal

Part de marché des médicaments contre les troubles de stockage lysosomal

Latest Developments in Lysosomal Storage Disorder Drugs Market

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

Table des matières

Liste des tableaux

Liste des figures

Méthodologie de recherche

Personnalisation disponible

Questions fréquemment posées

Parcourir les pages associées